Proprotein Convertase Inhibition Results in Decreased Ski Proliferation, Tumorigenesis, and Metastasis  by Bassi, Daniel E. et al.
Proprotein Convertase Inhibition
Results in Decreased Skin Cell
Proliferation, Tumorigenesis,
and Metastasis1,2
Daniel E. Bassi, Jirong Zhang, Jonathan Cenna,
Samuel Litwin, Edna Cukierman
and Andres J.P. Klein-Szanto
Department of Pathology, Fox Chase Cancer Center,
Philadelphia, PA, USA
Abstract
PACE4 is a proprotein convertase (PC) responsible for cleaving and activating proteins that contribute to enhance
tumor progression. PACE4 overexpression significantly increased the susceptibility to carcinogenesis, leading to
enhanced tumor cell proliferation and premature degradation of the basement membrane. In the present study,
we sought to evaluate a novel approach to retard skin tumor progression based on the inhibition of PACE4. We used
decanoyl-RVKR-chloromethylketone (CMK), a small-molecule PC inhibitor, for in vitro and in vivo experiments. We
found that CMK-dependent blockage of PACE4 activity in skin squamous cell carcinoma cell lines resulted in impaired
insulin-like growth factor 1 receptor maturation, diminished its intrinsic tyrosine kinase activity, and decreased tumor
cell proliferation. Two-stage skin chemical carcinogenesis experiments, together with topical applications of CMK,
demonstrated that this PC inhibitor markedly reduced tumor incidence, tumor multiplicity, and metastasis, pointing
to a significant delay in tumor progression in wild-type and PACE4 transgenic mice. These results identify PACE4,
together with other PCs, as suitable targets to slow down or block tumor progression, suggesting that PC inhibition
is a potential approach for therapy for solid tumors.
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Introduction
Proprotein convertases (PCs) are serine proteases that participate in the
posttranslational activation of inactive proteins leading to mature, ac-
tive proteins [1,2]. The family comprises several members: PC1/3,
PC2, PC4, PC5, PC7, furin, PACE4, subtilisin kexin isoenzyme 1,
and neuronal apoptosis-regulated convertase 1. Many of the PCs protein
substrates such as matrix-degrading enzymes [3], growth factors, growth
factor receptors, and adhesion proteins [4,5] have a direct role in tumor
progression. Overexpression of PCs has been documented in a variety of
neoplasms, including those from skin, lung, ovary, nervous system, and
colon [6–9], some leading to increased processing of their cognate sub-
strates [10]. Although all of these proteases recognize and cleave at the
C-terminus of the motif RXKR, differences in substrates preferences
[11], inhibition kinetics [12,13], and the phenotypes of the different
PC’s knockout animals [14] suggest some degree of heterogeneity in
PC functions. In this context, we demonstrated a preferential overexpres-
sion of PACE4 in chemically induced skin tumors and its role promot-
ing cell proliferation and basement membrane degradation, pointing
to a unique role of this PC in murine skin cancer [15]. The tumor-
enhancing characteristic of PACE4 suggested that inhibition of this
PC’s activity would result in decrease proliferation and tumor develop-
ment. PACE4, as the other PC’s, is activated in the trans-Golgi network
and transported into vesicles to the extracellular compartment [16,17].
PACE4 is an extracellular PC that binds several components of the extra-
cellular matrix, such as heparan sulfate proteoglycans [18]. PACE4
anchors to extracellular matrix components through its cysteine-rich
domain, facilitating its localization to the cell membrane and the pro-
cessing of its membrane associated substrates [19]. Also, it has been pro-
posed that PACE4may be activated in the cell surface pointing to a novel
mechanism for PC action [20].
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Insulin-like growth factor 1 receptor (IGF-1R) is a crucial PC sub-
strate involved in cell proliferation and is the first component of the
IGF-1–mediated signal transduction pathway [8,21]. Because blockage
of PACE4 activity in vivo may lead to the impairment of the IGF-1
signal transduction pathway [22], we sought to demonstrate the fea-
sibility of this novel therapeutic approach to delay skin tumor pro-
gression in a paradigmatic animal model of human cancer, that is, a
two-stage skin carcinogenesis.
Experiments based on tumor cell transfections demonstrated that the
Portland variant of α1-antitrypsin protein [12] mediated the inhibition
of PC activity, resulting in decreased proliferation [8,9,23,24], invasion
[23], or adhesion to extracellular matrix proteins [21,25] or endothelial
cells [21]. To determine the usefulness of PACE4 as a target for cancer
therapy, we evaluated the effects of its inhibition on epidermal cell pro-
liferation and in vivo tumor development. To this effect, we selected the
small-molecule decanoyl-RVKR-chloromethylketone (CMK) [26] that
successfully blocked cell proliferation [10,27] and invasion in cell-based
assays [24,28,29], contains a hydrophobic moiety that may favor its ab-
sorption into the skin, and could potentially be used as a topical agent.
Furthermore, CMK is commercially available.
In this article, we provide evidence that CMK-dependent in vivo in-
hibition of PACE4 activity results in decreased epidermal basal keratino-
cyte proliferation, tumor development, and metastasis, demonstrating
that inhibition of PCs has the potential to be a therapeutic tool.
Materials and Methods
Cell Lines and Transfection Procedures
We used mouse skin cell lines, including line 308 obtained form nor-
mal adult keratinocytes [30], a line derived from a skin papillomaMT1/2,
and lines derived from carcinomas JWF-2, CH72, and CH72T3, gen-
erously provided byDr Susan Fischer (MDACCScience Park, Smithville,
TX). These cells were selected because they originated from papillomas
and squamous cell carcinomas (SCCs) from mice treated with chemical
carcinogens. In addition, we included two isogenic cell lines, isolated
in our laboratory, derived form a low-grade SCC (CC4B) and spindle
cell carcinoma (CC4A) [31]. All cells were grown in spinner minimal
essential medium eagle (s-MEM) medium containing 10% fetal bovine
serum, 2 mM L-glutamine, and penicillin-streptomycin (Pen-Strep,
Cellgro, Manassas, VA) (100 U/ml and 100 mg/ml, respectively). Pri-
mary epidermal keratinocytes were prepared as described in a previous
publication [15].
Small Interference RNA
PACE4 small interference RNA (siRNA) was synthesized using the
pSilencer siRNa Construction Kit (Ambion, Austin, TX). The tem-
plate sequences were obtained from RNAi Central, a Web page from
Hannon Laboratory (http://katahdin.cshl.org:9331/homepage/portal/
scripts/main2.pl).
The sequences used as templates are shown in Table 1.
PACE4 Enzymatic Assay
PACE4 catalyses the hydrolysis of the synthetic substrate Boc-RXKR-
AMC into Boc-RXKR and aminomethylcoumarine (AMC). The latter
is a fluorescent compound that can be used to monitor the extent of the
reaction. Reactions were performed as previously described [32]. Briefly,
conditioned medium from cell cultures was incubated for 17 hours at
30°C in the presence of Boc-RXKR-AMC (50 μM), 100 mM HEPES
(pH 7.5), 0.5% Triton X-100, and 1 mMCaCl2. To assess the extent of
CMK inhibition, we evaluated PACE4 activity in the presence of CMK
(0.1-200 μM). After completion of the reaction, we measured of AMC
liberated in a plate reader spectrofluorometer, using the program Cary
Eclipse, Varian Inc (λabsorption = 380 nm, λemission = 460 nm, 800 V of
sensitivity). Experiments were performed in triplicates.
Western Blot Analyses
Cell lysis and Western blot were performed using 50 μg of cell lysates
as described previously [33]. Antibodies used for immunoblot analysis
included anti–IGF-1R β-subunit (Santa Cruz Biotechnology, Inc, Santa
Cruz, CA) and a monoclonal antibody anti–phospho-IGF-1R, anti–
extracellular signal–regulated kinase 1/2 (ERK1/2), and anti–phospho-
ERK1/2 (Cell Signaling Inc, Beverly, MA). Filters were incubated with
the appropriate secondary horseradish peroxidase–conjugated antirabbit
or antimouse (Amersham, Piscataway, NJ) antibodies.
Proliferation Assay
In vitro cell proliferation was measured as incorporation of [3H]
methyl thymidine into DNA as described elsewhere [8,23].
CMK Labeling, Absorption Experiments, and
Fluorescence Microscopy
CMKwas diluted to 2 mM in DMSO and 0.01 M carbonate buffer
(pH 9). Equimolecular quantities of fluorescein isothiocyanate (FITC;
10 mM in DMSO) were added with constant stirring. The reaction
mix was incubated for 2 hours at room temperature protected from
light. A thin precipitate corresponding to the FITC derivative separated
from the reaction mixture. The reaction was stopped by the addition of
2 μl of 0.1 M phosphate buffer pH 7.4, and the crude precipitate was fil-
trated through Microcon 10 filters (Millipore, Billerica, MA) and washed
withmethanol to remove the excess of FITC andDMSO. The filtrate was
analyzed for the presence of FITC by thin-layer chromatography (silica
gel, developed with acetone, Rf FITC = 0.91, Rf neutralized product =
0.3). The precipitate was washed until FITC was no longer detectable
using this system. The washed precipitate containing FITC-labeled
CMK (FITC-CMK) was finally dissolved in acetonitrile/2% formic acid;
the purity of the product was confirmed by C-18 HPLC column and
analyzed by mass spectrometry (calculated mass = 1133, found = 1133,
main peak = 1079).
To determine the skin absorption of FITC-CMK, female K5-PACE4
transgenicmice that overexpress the PCunder the control of the keratin-5
promoter in squamous epithelia [15] were used after shaving the dorsal
skin. The following day, the animals were treated by topical application
of a solution of either 100 μM or 1 mM of FITC-CMK. As controls,
animals were treated with acetone or 1mMFITC alone. One hour there-
after, the animals were killed; the skin was dissected and immediately
frozen inOCTembeddingmedium (Tissue-Tek, Torrance, CA). Samples
were mounted with fluorescent mounting medium (Prolong Gold anti-
fade reagent; Molecular Probes, Eugene, OR).
Table 1. SiRNA Templates.
Template Sequence
mPACE4 1 Forward 5′AACGCGAAGTGACTCTCTTTACCTGTCTC 3′
Reverse 5′AATAAAGAGAGTCACTTCGCGCCTGTCTC 3′
mPACE4-2 Forward 5′AAGCGAGCGACTGGAAAGTCACCTGTCTC 3′
Reverse 5′AATGACTTTCCAGTCGCTCGCCCTGTCTC 3′
mPACE4 scr Forward 5′AACGGTGCAGACTGAACGAAGCCTGTCTC 3′
Reverse 5′AACTTCGTTCAGTCTGCACCGCCTGTCTC 3′
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Frozen sections (5 μm) from the FITC-CMK–labeled skins were
analyzed by fluorescence microscopy. Imaging was done in a microscope
(Eclipse TE 2000-U;Nikon,Melville, NY) using a magnification of 60×
(NA = 1.4) by excitation at 364 nm. Pictures were obtained with a cam-
era (CoolSNAPHQ; Roper Scientific, Tucson, AZ), with an exposure of
1 second, and processed using Metamorph software (Molecular Devices
Inc, Downingtown, PA). For quantitative measurements of fluorescence,
the images were visualized in pseudocolor to enhance the levels
of fluorescence, and the difference between the fluorescence of the
image and the background was recorded and plotted in a bar diagram.
Skin Carcinogenesis
We used wild-type FVB × FVB mice purchased from Taconic as
controls. Transgenic K5-PACE4 animals were generated in house as
described elsewhere [15]. These transgenic mice express PACE4 un-
der the control of the keratin 5 promoter, which restricts its expres-
sion to the basal layer of squamous epithelia.
A single 100-nmol initiating dose of 7,12-dimethylbenz(a)anthracene
(DMBA) in 0.2 ml of acetone was applied topically to the shaved dorsal
skin of 6- to 8-week-old female mice. One week after DMBA treatment,
12-O-tetradecanoylphorbol-13-acetate (TPA) (4 μmol) in 0.2 ml of ace-
tone or acetone alone was applied twice weekly to the skin for the dura-
tion of the experiment (30 weeks). Wild-type and PACE4 transgenic
animals were subdivided in two groups: control (treated with TPA only,
twice a week) or CMK (Alexis Corp, San Diego, CA; treated five times a
week, 100 μM final concentrations).
Tumor incidence and multiplicity were observed weekly starting at
8 weeks of TPA promotion. Three sets of experiments were performed.
The combined number of mice per group was as follows: DMBA +
TPA, 20 wild-type mice and 35 PACE4 transgenic mice; DMBA +
TPA + CMK, 25 wild-type mice and 57 transgenic mice. Papillomas
and SCCs were recorded by gross observation as exophytic cauliflower-
like small tumors or as infiltrating and/or ulcerating lesions, respec-
tively, and were confirmed by histopathologic analysis. Autopsies of
carcinoma-bearing mice were done, and metastasis in axial lymph
nodes, lung, liver, and spleen was recorded. All experiments have been
reviewed and approved by the Fox Chase Cancer Center IACUC.
Tumor volume was calculated as described before [34].
Histology and Immunohistochemistry
Paraffin sections obtained from control (untreated) and CMK-
treated skin from K5-PACE4 mice were fixed in phosphate-buffered
10% formaldehyde and embedded in paraffin. Histologic and immuno-
histochemical analysis was performed using 5-μm-thick paraffin sections.
Immunohistochemistry was performed using the IGF-1R, pIGF-1R,
antibodies described under Western blot analysis. The proliferative
marker Ki-67 was detected with a monoclonal rat anti-67 antibody from
DAKO (cl.T-3; Glostrup, Denmark). An avidin-biotin-peroxidase kit
Figure 1. PACE4 expression and activity in murine skin cell lines. NK and 308, normal murine keratinocytes; MT1/2, papilloma cell line; all
others, SCC cell lines. DNAse-treated messenger RNA was analyzed for PACE4 expression by reverse transcription–polymerase chain re-
action (A) and quantified by real-time quantitative reverse transcription–polymerase chain reaction (B). The conditioned media from these
cells were tested for PC proteolytic activity and evaluated as production of the fluorescent product AMC (C). Note that PACE4 expression
directly correlates with enzymatic activity. GAPDH indicates glyceraldehyde-3-phosphate dehydrogenase.
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(Vectastain Elite, Burlingame, CA), followed by the chromagen 3′,3′-
diaminobenzidine, was used following the manufacturer’s instructions.
Negative controls, not incubated with the primary antibodies, were first
incubated with either normal rabbit or mouse serum. All sections were
counterstained with hematoxylin and were mounted.
Statistical Analysis
To test the statistical significance of the differences of tumor develop-
ment a Wilcoxon two-sample tests and two-tailed t-test were used. The
differences in metastasis were determined by a Fisher exact test. The
P values for the differences in the slope of the tumor development curves,
the simple linear regression techniques, and the t-test were used to calcu-
late the slope, the SD of the slope, and the confidence interval (α = 0.05).
Results
PACE4 Expression and Activity Correlated with Cell
Line Aggressiveness
Previous studies demonstrated that ectopic expression of PACE4 con-
ferred benign tumors cells the ability to invade surrounding normal tissues
[35]. To demonstrate the association of PACE4 and neoplastic transforma-
tion, we determined its expression levels and activity in several murine
tumor cell lines and compared them with primary cultures of normal epi-
dermal keratinocytes. Most of the cancer cell lines tested expressed higher
levels of PACE4 messenger RNA, proteins, and enhanced proteolytic ac-
tivity than a cell line derived fromnormal adultmurine keratinocytes (308;
Figure 1, A and B). The other PCs did not show this clear tendency in
murine cell lines. Furin was expressed in nearly all cell lines, whereas
PC5 was not detected. PC7 expression increased moderately from normal
to cancer cell lines (Figure 1A). For further studies, we selected JWF-2 and
CH72, cell lines of rapid growth and invasiveness both in vivo and in vitro
[36], characterized by high PACE4 activity (Figure 1C). This activity was
clearly attributable to this PC because silencing PACE4 expression using
a combination of two specific siRNA resulted in a 50% decrease of the
extracellular PACE4 proteolytic activity (Figure 2A).
To inhibit PACE4 activity, we used the small PC inhibitor molecule,
CMK. First, we established the CMK doses that were effective in re-
ducing the cleavage of Boc-RVRR-AMC, a synthetic substrate for
PCs, in JWF-2 and CH72 cell lines. Treatment of both cell lines with
CMK showed that PACE4 activity was significantly reduced in a dose-
dependent manner (Figure 2B).
In Vitro Inhibition of PACE4 Leads to Decreased IGF-1R
Maturation and Phosphorylation
One of the main processes altered during tumor development is the
IGF-1 mediated proproliferative signals transduced through its receptor
IGF-1R, a known PC substrate [8]. Complete activation of this recep-
tor and phosphorylation was observed in both CH72 and JWF-2 cell
lines. Decreased IGF-1R processing (Figure 3A) resulted in impair-
ment of its intrinsic tyrosine kinase activity (Tyr 1131 autophosphor-
ylation) as evidenced by a remarkable dose-dependent reduction of
receptor phosphorylation levels, indicating that cells became refractory
to IGF-1 signaling. Decreased receptor phosphorylation resulted in di-
minished phosphorylation of ERK1 and ERK2 (Figure 3B), well-known
downstream substrates of the IGF-1R signal transduction pathway.
CMK-dependent inhibition of IGF-1R processing altered this signal
transduction pathway and its biologic end point, cell proliferation, mea-
sured as incorporation of [3H]-thymidine into newly synthesized DNA
(Figure 4, A and B).
FITC-CMK Penetrates through the Epidermis in a
Dose-Dependent Manner
The epidermis represents an effective barrier, protecting the underly-
ing tissues from exogenous chemical injuries, and limiting drug admin-
istration through topical application. Before the use of the two-stage skin
chemical carcinogenesis protocol, we determined whether CMK was
able to overcome this natural barrier. To determine whether CMK
reaches the basal cells of the epidermis where the transgene is expressed,
we derivatized CMK by the sole addition of FITC in the basic lysine
residue. The more basic arginine residues (three basic residues per argi-
nine; total six basic residues) are not modified because being ionized at
the conditions of the addition reaction (pH = 9) indicates being poor
nucleophiles. The addition of FITC adds a fluorescent label to facilitate
its visualization in frozen sections. However, addition of FITC to the
lysine groups renders the compound inactive because blockage of this
basic residue abrogates its ability to bind to the active site of PCs.
FITC-labeledCMKwas topically applied to the skin surface at 0.1 and
1 mM, respectively. The levels of penetration were assessed by fluores-
cence microscopy. As shown in Figure 5B, CMK penetrated through
the skin at a concentration of 0.1 mM and could be detected homoge-
neously distributed throughout the epidermis. Application of a 1-mM
solution resulted in a notorious increased penetration through the epi-
dermis and some areas of fluorescent accumulation (Figure 5C ). Un-
treated skin showed no detectable levels of fluorescence, demonstrating
that skin autofluorescence was not present (Figure 5A), even after photo-
graphic exposures of up to 10 seconds (Figure W1). FITC alone (with-
out CMK) remained at the surface of the epidermis, unable to pass
through the stratum corneum, a behavior previously reported with other
Figure 2. (A) Small interference RNA–mediated silencing of PACE4
expression resulted in decreased proteolytic activity in the conditioned
medium extracted form the highly PACE4-expressing cells JWF-2 and
CH72: P< .0001, P< .05, respectively. (B) CMK-dependent inhibition
of PC activity. Conditionedmedium from the JWF-2 andCH72cell lines
were collected and assayed for PC proteolytic activity in the presence
of increasing amounts of CMK. The enzymatic activity was evaluated
as the production of the fluorescent product AMC: P< .002.
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nondiffusible molecules [37], thus excluding that the addition of mod-
erately hydrophobic moiety, FITC, to the drug was responsible for its
penetration through the epidermis (Figure W1D). Furthermore, the ad-
dition of FITC, which increases the molecular weight in approximately
300, does not seem to impair the ability of the CMKmoiety to drive the
absorption of CMK through the skin.
In Vivo PACE4 Inhibition Impairs Epidermal Proliferation
After assessing the epidermal absorption of CMK, we sought to
determine the short-term effects of CMK on skin physiology. As we ex-
pected to apply CMK to the skin, we first analyzed this organ for putative
toxic effects. Altered cell morphology, pyknotic nuclei, or inflammatory
cells were not apparent even after topical skin treatment with a high dose
(0.5 mM) of CMK for five consecutive days. Furthermore, no systemic
effects were detected in any animals treated with CMK in the complete
autopsies that were performed in all treated animals.
To study the possible blockage in proliferation in vivo, before the
CMK application, the skin was topically treated with the hyperplasio-
genic phorbol ester TPA to increase the usually low-basal keratinocyte
proliferation level. IGF-1R phosphorylation was assessed by immuno-
histochemistry after a 2-day treatment either with vehicle alone (acetone)
or with CMK. Although the expression of total IGF-1Rwas not affected
by CMK (Figure 6, A and B), a complete absence of phosphorylation
was observed after CMK treatment (Figure 6, C and D), mirroring
the inhibition of IGF-1–mediated signal transduction observed in vitro.
These results support the fact that CMK-mediated inhibition of PACE4
Figure 3. CMK inhibits IGF-1Rmaturation and phosphorylation. Cells were incubated in the absence or presence of different concentrations
of CMK. Cells were plated and incubated with CMK and serum-containing media. After 24 hours, the mediumwas replaced with serum-free
medium containing the same CMK concentrations. On the third day, cells were induced with 50 nM IGF-1 for different incubation periods as
indicated. pIGF-1R and the extent of processing of IGF-1R (A) or ERK1/2 phosphorylation (B) were evaluated byWestern blot. Note that CMK
abolished almost completely IGF-1R phosphorylation even at the lowest CMK concentration.
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results in disruption of the IGF-1 signaling pathway by decreasing the
receptor’s tyrosine kinase activity. No significant differences in the rate
of proliferation between treated and untreated epidermis was observed
after 2 days. To better evaluate the effects of CMK on cell proliferation
in vivo, CMK treatment was thus extended for 3 weeks. WT and K5-
PACE4 transgenic mice were treated with TPA to induce epidermal
cell proliferation. Immunohistochemistry with the proliferation marker
Ki-67 showed that CMK treatment was very effective in decreasing the
number of Ki-67–labeled cells in both K5-PACE4 mice epidermal basal
epidermal keratinocytes (approximately 57% less proliferative than non–
CMK-treated epidermis) and wild-type mouse epidermis treated with
CMK (45%; Figure 7, A–E).
In Vivo PACE4 Inhibition Results in Decreased Skin
Tumor Development
The inhibition of basal keratinocyte proliferation observed in the
short-term experiments described may result in delayed tumor develop-
ment and progression. To test this hypothesis, wild-type mice and K5-
PACE4 transgenic mice were treated with a two-stage carcinogenesis
protocol to induce tumor formation and concomitantly treated five
times weekly either with CMK (1 mg/kg, or 100 μM CMK, 200 μL)
dissolved in acetone, or with the vehicle alone, starting at week 2.
As previously described, wild-type mice developed more papillomas
than transgenic mice [15], suggesting that PACE4 expression favors the
formation of SCCs without undergoing the usual papilloma-SCC
sequence. Although CMK only marginally affected papilloma growth
(Figure 8, A and B), it exerted a clear and consistent inhibition of tumor
progression to SCC (Figure 8, C and D). As expected, CMK treat-
ment of PACE4 transgenic mice showed a reduction of 37% in SCC
multiplicity, exhibiting 0.9 SCC/mouse after 30 weeks of treatment
(Figure 8D). This contrasted with 1.4 SCC/mouse observed in the con-
trol non–CMK-treated group of transgenic mice (P < .01; Figure 8C).
Wild-type mice were less responsive to CMK, showing a reduction of
29% in the number of SCC per mouse (Figure 8C ; P = .059). Further-
more, in CMK-treated K5-PACE4 mice, the rate of carcinoma growth
decreased 25%, when compared with the untreated mice as shown by
the reduced slopes in the linearized curves of multiplicity versus time
(Figure 9). In addition, CMK applications resulted in decreased tumor
volumes of approximately 50% in both wild-type and transgenic mice
(Figure 10A).
Topical applications of CMK also decreased the metastatic potential
of skin SCCs. When evaluated after 30 weeks of promotion, 30% of
the untreated animals developed lung metastases. This contrasted with
13% of mice with pulmonary metastases in the CMK-treated group
(P = .045). The difference in lymph node metastasis incidence was less
impressive, that is, 60% of untreated animals versus 40% of CMK-
treated mice presented with this type of metastasis. These differences
were marginally significant (P = .057, Fisher exact test; Figure 10B).
Discussion
Increased activity and expression of metalloproteases and growth factors
often precedes the ability of tumor cells to proliferate, invade, and me-
tastasize. The serine protease PACE4 activates several tumor-related
biomolecules necessary to accomplish these newly acquired abilities.
Overexpression of PACE4 in murine cells leads to increased invasive
abilities both in vitro [31] and in vivo [15] has been described by our
laboratory, suggesting that inhibition of this PC’s activity may slow
down tumor development. The results presented herein, using a PC
inhibitor, indicate that inhibition of PACE4 activity lowered cell pro-
liferation in vitro and decreased skin proliferation and tumor devel-
opment in vivo. Decreased cell proliferation rates can be ascribed to
a reduction in IGF-1R processing and activation, leading to a less effi-
cient transduction of the IGF-1–mediated proproliferative signals.
PACE4 expression correlates with increased murine cell line invasive-
ness [31]. Its expression was two- to four-fold higher in tumor cell lines
than in normal primary keratinocytes and its higher expression corre-
lated with increased PC proteolytic activity in vitro [31]. One exception
to the rule was the papilloma-derived cell line MT1/2, which expressed
very low levels of PACE4 and exhibited moderate PC activity, indicat-
ing that enzymes other than PACE4 might be operating in this cell line.
Nevertheless, this atypical activity does not translate in an aggressive
phenotype because this particular cell line exhibits low cell proliferation
and invasiveness [38].
Because PACE4 is an extracellular protease, it can be detected and
assayed in the conditionedmedium of cultured cells. Incubation of con-
ditioned medium with CMK effectively decreased the cleavage of the
PC’s synthetic substrate, Boc-RVKR-AMC. This activity may bemainly
attributed to PACE4 because specific silencing of this PC’s expression
by a combination of twomurine PACE4 siRNA resulted in a significant
reduction of Boc-RVKR-AMC cleavage.
CMK-dependent inhibition of PACE4 resulted in decreased cleavage
of a prominent PC substrate, IGF-1R, that is directly associated with
tumor cell proliferation, followed by decreased IGF-1R phosphoryla-
tion, pointing to a reduced ability to transmit IGF-1–mediated sig-
nals. IGF-1R is responsible for many proproliferative and prosurvival
Figure 4. Inhibition of IGF-1R processing and phosphorylation re-
sults in decreased in vitro proliferation rates. Cells were subsequently
treated with the indicated CMK concentrations for 24 hours, starved
an additional 16 hours, and incubated in the presence of serum for
4 hours. Cells (A) JWF-2 and (B) CH72 were labeled with [3H]-methyl
thymidine for 4 hours. DNA was extracted, and the levels of radio-
activity associated with the newly synthesized DNA were measured
in a scintillation counter. Note the dramatic decreased in proliferation
in CMK-treated cells (P < .0001).
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responses, involving the MAPK or the PIK3/Akt pathways, respectively
[39,40]. In this context, CMK-treated cells showed reduced ERK1/2
phosphorylation, key proteins in the signal transduction pathway as-
sociated with IGF-1. IGF-1R processing and activation were not com-
pletely abolished by CMK even at the highest CMK concentrations
tested (100 μM), suggesting that a fraction of mature receptor could
still be capable of some levels of autophosphorylation. However, the
receptor phosphorylation and the consequent tumor cell proliferation
were greatly reduced, indicating that the presence of noncleaved recep-
tor might interact with the mature receptor, thus inhibiting the intrin-
sic kinase activity. Many mechanisms for this dominant-negative–like
activity were proposed, such as the sequestering of normal IGF-1R sub-
strates including IRS-1 [41] or the assembling of nonfunctional hybrids
between the noncleaved and cleaved receptors [42].
The reduction in proliferation rates observed in vitro suggested that
inhibition of PACE4-mediated activation of IGF-1R could derive in a
diminished susceptibility to carcinogens, resulting in decreased tumor
development. IGF-1–mediated signaling plays an important role in
skin carcinogenesis. For instance, transgenic mice overexpressing IGF-1
in basal keratinocytes exhibited increased susceptibility to chemical
carcinogenesis [43,44]. Moreover, IGF-1R expression is necessary for in-
ducing transformation in fibroblasts [45] and is responsible for decreased
keratinocyte differentiation and enhanced proliferation [46].
After confirming that PACE4 activity could be efficiently blocked
in vitro by CMK, we sought to determine whether CMK counteracts
the increased susceptibility of PACE4 transgenic mice to chemical
carcinogenesis [15]. CMK was applied five times a week for 30 weeks,
together with a two-stage chemical carcinogenesis protocol. Experi-
ments were terminated at 30 weeks because of the high tumor burden
displayed by control animals. The development of benign tumors
(papillomas) was not significantly altered by CMK treatment, suggest-
ing that PACE4 activity is more prominent during the later stages of
tumor conversion and progression. Previous results [15] showed that
PACE4 transgenic mice developed twice as many malignant tumors as
wild-type animals without increased growth of benign tumors. In this
report, we showed that the application of this PC inhibitor resulted in
a significant decrease in the number and in the rate of SCC devel-
opment, suggesting that CMK counteracts the proproliferative effects
of PACE4.
PACE4 also activates substrates involved in cell invasiveness, such as
membrane type-matrix metalloproteases [35]. After PC-mediated ac-
tivation, metalloproteases degrade the epithelial basement membrane,
Figure 5. FITC-CMK skin penetration. CMKwas labeledwith FITC, purified, and analyzed by HPLC/MS. FITC-CMK–treated skin sectionswere
analyzedwith theMetamorph software using pseudocolor to assess the relative amount of fluorescence in the epidermis (Epi), dermis (Der),
and skin surface (Sur). Sham (A), 100 μM (B), and 1 mM FITC-CMK (C) treatments, respectively. The epidermal fluorescence was subtracted
from background levels and plotted in a bar diagram (D). Exposure time: 1 second, (P = .001).
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allowing a premature interaction between stromal components and the
epithelial cells, resulting in increased proliferation and accelerated stromal
invasion [15]. Blockage of PACE4 activity also resulted in decreased in-
vasiveness, as evidenced by a reduction in lymph nodes metastasis and
especially by a significantly lower incidence in pulmonary metastases in
CMK-treated animals.
Interestingly, both WTand K5-PACE4 transgenic mice subjected to
a two-stage carcinogenesis protocol showed a reduction in SCC multi-
plicity and metastasis after CMK treatment. Nevertheless, cancer reduc-
tion after CMK application inWTmice was less marked and significant
than in K5-PACE4 animals. Although this effect in WTmice indicate
that CMK is able to block endogenous PCs present in the skin, such
Figure 6. CMK-dependent inhibition of TPA-induced epidermal proliferation. The skin of K5-PACE4 transgenic mice was treated with vehicle
(A and C) or CMK (300 μm; B and D) for 2 days before TPA treatment. Tissues were collected and fixed, and the relative expression of total
and phosphorylated IGF-1R was assessed by immunohistochemistry. Note the decrease in IGF-1R phosphorylation in the hair follicles in the
treated epidermis despite the relative constant IGF-1R expression. pIGF-1R immunohistochemistry and hematoxylin counterstain.
Figure 7. Skin fromwild-type (A and B) or Tg (K5-PACE4; C and D) mice were treated with TPA (twice weekly) to increase the low basal level
of cell proliferation and then treated either with vehicle alone (A and C) or with CMK 100 μM (B and D) daily for 2 weeks. Fragments of dorsal
skin were fixed and embedded in paraffin; sections were stained with anti–Ki-67 antibody. The number of labeled basal epidermal keratino-
cytes was measured per length of interfollicular epidermal basement membrane and expressed as positive cells per millimeter of basement
membrane (E) P < .001. Original magnification, ×100.
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as epidermal furin and PC7, the transgenic overexpression of PACE4
in K5-PACE4 transgenic mice emphasized and clearly demonstrated
the inhibitory effect of the drug on PACE4 activity.
Taken together, our in vitro and in vivo results provide evidence that
PACE4 may represent a new target for cancer therapeutics. Current PC
research has focused on the inhibition of furin, the prototype of the
PC family. In fact, inhibition of furin has proved successful in block-
ing cancer cell growth and invasion in colorectal [21], breast [22], and
head and neck cancer [23], among others. Furthermore, PC5 and PC7
inhibition resulted in inhibition of VEGF-C [47,48], a key factor in
angiogenesis and tumor nourishment and development, showing some
promise in the development of new PC inhibitors. Nevertheless, recent
Figure 8. CMK inhibitory effect on tumor multiplicity. Wild-type and transgenic (Tg; K5-PACE4) mice were initiated with DMBA and treated
with TPA twice aweek for 30weeks in the presence or absence of CMK (100 μM, starting at week 2). The numbers of papillomas permouse in
wild-type (A) and K-PACE4 mice (B) and SCC per mouse in wild-type (C; P< .05) or K5-PACE4 animals (D; P< .01) were determined weekly.
Figure 9. Analysis of SCC growth rate patterns in CMK-treated (100 μM) and untreated mice. Tumor multiplicity curves were adjusted to fit
linear functions, and the slopes, intercept, and their SDs were calculated by regression analysis. The confidence interval of the slope and the
P value to reject the null hypothesis were determined using a t distribution. (A) Linear approximation of tumor multiplicity curves versus time
for K5-PACE animals. (B) Mean slopes with their SDs.
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studies in Apc/Min+ mice demonstrated that expression of PC5/6 had
a protective effect on intestinal cancer development, indicating that
specific PC5 inhibitors may be beneficial in some malignancies [48].
PACE4 has been associated with activation of cancer molecules. How-
ever, its down-regulation in ovarian cancer [6,49], and its association
with increased breast tumorigenesis [22] points to a different role of
this protease in cancer. Unlike furin, PACE4 is an extracellular protease
that may be more extensively regulated by extracellular signals. In this
context, the breast or ovarian stroma may exert a different effect on
PACE4 activity that the basement membrane, or that the strong hor-
monal influences may point to a different role of PACE4 in these can-
cers. We have previously found that increased expression of PACE4 in
the basal layer of the epidermis resulted in increased disruption of the
collagen component of the basement membrane and increased activa-
tion of metalloproteinases [15]. Our results point to a beneficial effect
of PACE4 inhibition on the development of skin cancer as a result of
decreased cell proliferation and invasion in the unique context of the
basement membrane-epithelial interaction [21]. Blockage of PACE4
activity disrupts IGF-1 signaling, leading to impaired proliferation. Fur-
thermore, continuous in vivo inhibition of PACE4 activity by CMK
resulted in early decrease of tumor cell proliferation, delayed tumor de-
velopment, as well as reduction in tumor incidence, tumor multiplicity
and metastasis in a paradigmatic model of squamous carcinogenesis.
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Figure W1. Specificity of FITC-CMK skin penetration. (A–C) Skin sections of acetone- (sham) treated skin. Pictures of the specimens were
taken by exposing for 1 (A), 5 (B), or 10 (C) seconds. Note the minimal amount of fluorescence even at 10 seconds of exposure. Dotted line
shows the basement membrane. (D) FITC-treated skin section. Note that FIC accumulated mostly in the superior layers of the epidermis
(Epi). Der indicates dermis; Sur, skin surface.
